A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

Arthritis & Rheumatism ◽

10.1002/art.24699 ◽

2009 ◽

Vol 61 (9) ◽

pp. 1168-1178 ◽

Author(s):

Daniel J. Wallace ◽

William Stohl ◽

Richard A. Furie ◽

Jeffrey R. Lisse ◽

James D. McKay ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Phase Ii ◽

Lupus Erythematosus ◽

Active Systemic Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus

Arthritis & Rheumatology ◽

10.1002/art.41179 ◽

2020 ◽

Vol 72 (5) ◽

pp. 761-768 ◽

Author(s):

Ronald F. Vollenhoven ◽

Bevra H. Hahn ◽

George C. Tsokos ◽

Peter Lipsky ◽

Kaiyin Fei ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Phase Ii ◽

Lupus Erythematosus ◽

Crossover Trial ◽

Active Systemic Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study

Arthritis & Rheumatism ◽

10.1002/art.27189 ◽

2010 ◽

Vol 62 (1) ◽

pp. 201-210 ◽

Author(s):

Annett M. Jacobi ◽

Weiqing Huang ◽

Tao Wang ◽

William Freimuth ◽

Inaki Sanz ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

B Cells ◽

Phase Ii ◽

Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Arthritis & Rheumatology ◽

10.1002/art.39856 ◽

2017 ◽

Vol 69 (2) ◽

pp. 362-375 ◽

Author(s):

Megan E. B. Clowse ◽

Daniel J. Wallace ◽

Richard A. Furie ◽

Michelle A. Petri ◽

Marilyn C. Pike ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Active Systemic Lupus Erythematosus ◽

Phase Iii ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Two Phase ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus

Rheumatology and Therapy ◽

10.1007/s40744-021-00351-7 ◽

2021 ◽

Author(s):

Anca D. Askanase ◽

Dale Wright ◽

Enxu Zhao ◽

Julie Zhu ◽

Roman Bilyk ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Controlled Trial ◽

Active Systemic Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Rheumatology and Therapy ◽

10.1007/s40744-021-00353-5 ◽

2021 ◽

Author(s):

Anca D. Askanase ◽

Enxu Zhao ◽

Julie Zhu ◽

Roman Bilyk ◽

Richard A. Furie

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Controlled Trial ◽

Active Systemic Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.714897805.790252957 ◽

2012 ◽

Author(s):

Tsutomu Takeuchi ◽

Hideto Kameda

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Repeat Dose ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-202760 ◽

2013 ◽

Vol 73 (1) ◽

pp. 183-190 ◽

Author(s):

Daniel J Wallace ◽

Kenneth Kalunian ◽

Michelle A Petri ◽

Vibeke Strand ◽

Frederic A Houssiau ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Multicentre Study ◽

Lupus Erythematosus ◽

Active Systemic Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Rheumatology and Therapy ◽

10.1007/s40744-020-00236-1 ◽

2020 ◽

Vol 7 (4) ◽

pp. 893-908 ◽

Author(s):

Anca D. Askanase ◽

Enxu Zhao ◽

Julie Zhu ◽

Roman Bilyk ◽

Richard A. Furie

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Controlled Trial ◽

Active Systemic Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.714897805.791652962 ◽

2012 ◽

Author(s):

Ann Reed ◽

Vaidehi Chowdhary

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Repeat Dose ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717976439.793474960 ◽

2013 ◽

Author(s):

Joan Merrill

Keyword(s):

Systemic Lupus Erythematosus ◽

Multicentre Study ◽

Lupus Erythematosus ◽

Active Systemic Lupus Erythematosus ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo

Download Full-text